These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 18177781)

  • 1. Objective and perspective determine the choice of composite endpoint.
    Borm GF; Teerenstra S; Zielhuis GA
    J Clin Epidemiol; 2008 Feb; 61(2):99-101. PubMed ID: 18177781
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dependence, hyper-dependence and hypothesis testing in clinical trials.
    Moyé LA; Baraniuk S
    Contemp Clin Trials; 2007 Jan; 28(1):68-78. PubMed ID: 16857430
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Methods of determining sample sizes in clinical trials.
    Jeyaseelan L; Rao PS
    Indian Pediatr; 1989 Feb; 26(2):115-21. PubMed ID: 2753525
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Conducting a cost-effectiveness trial in oncology: justification and method].
    Lejeune C; Binquet C; Bonnetain F
    Bull Cancer; 2009 May; 96(5):603-7. PubMed ID: 19435689
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Subject-own-control designs from a statistical perspective.
    Fleiss JL
    Psychopharmacol Bull; 1979 Jul; 15(3):42-4. PubMed ID: 493461
    [No Abstract]   [Full Text] [Related]  

  • 6. Does the decision in a validation process of a surrogate endpoint change with level of significance of treatment effect? A proposal on validation of surrogate endpoints.
    Sertdemir Y; Burgut R
    Contemp Clin Trials; 2009 Jan; 30(1):8-12. PubMed ID: 18809512
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Assessing the impact of ICH E9.
    Brown D; Day S; Hemmings R; Wright D
    Pharm Stat; 2008; 7(2):77-87. PubMed ID: 18438957
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical trials with allergen products--statistical considerations.
    Volkers P
    Arb Paul Ehrlich Inst Bundesamt Sera Impfstoffe Frankf A M; 2006; (95):172-80; discussion 181. PubMed ID: 17393737
    [No Abstract]   [Full Text] [Related]  

  • 9. Design and endpoints of clinical trials in hepatocellular carcinoma.
    Llovet JM; Di Bisceglie AM; Bruix J; Kramer BS; Lencioni R; Zhu AX; Sherman M; Schwartz M; Lotze M; Talwalkar J; Gores GJ;
    J Natl Cancer Inst; 2008 May; 100(10):698-711. PubMed ID: 18477802
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A new 'mechanistic-practical" framework for designing and interpreting randomized trials.
    Karanicolas PJ; Montori VM; Devereaux PJ; Schünemann H; Guyatt GH
    J Clin Epidemiol; 2009 May; 62(5):479-84. PubMed ID: 18468856
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Proceedings of the Symposium on Designs for Clinical Cancer Reseach. Discussion I: Basic design considerations.
    Cancer Treat Rep; 1980; 64(2-3):411-7. PubMed ID: 7407778
    [No Abstract]   [Full Text] [Related]  

  • 12. Proceedings of the Symposium on Designs for Clinical Cancer Research. Perspective of the clinician.
    Hoogstraten B
    Cancer Treat Rep; 1980; 64(2-3):537-8. PubMed ID: 7407796
    [No Abstract]   [Full Text] [Related]  

  • 13. [Decision making in clinical research: a statistical approach].
    Lacaine F; Huguier M
    Gastroenterol Clin Biol; 1980 Nov; 4(11):754-7. PubMed ID: 7461386
    [No Abstract]   [Full Text] [Related]  

  • 14. [Controlled randomized clinical trials].
    Jaillon P
    Bull Acad Natl Med; 2007; 191(4-5):739-56; discussion 756-8. PubMed ID: 18225427
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Methodological and statistical aspects of equivalence and non inferiority trials].
    Elie C; De Rycke Y; Jais JP; Marion-Gallois R; Landais P
    Rev Epidemiol Sante Publique; 2008 Aug; 56(4):267-77. PubMed ID: 18703296
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of the statistical power for multiple tests: a case study.
    Yeo A; Qu Y
    Pharm Stat; 2009; 8(1):5-11. PubMed ID: 18381588
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Statistical methods in clinical trials.
    Gebski VJ; Keech AC
    Med J Aust; 2003 Feb; 178(4):182-4. PubMed ID: 12580749
    [No Abstract]   [Full Text] [Related]  

  • 18. [Quality of clinical information (II): Statistical significance].
    Plasencia A; Porta Serra M
    Med Clin (Barc); 1988 Jan; 90(3):122-6. PubMed ID: 3280891
    [No Abstract]   [Full Text] [Related]  

  • 19. The clinical significance of statistical significance.
    Kane RC
    Oncologist; 2008 Nov; 13(11):1129-33. PubMed ID: 18984874
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [From empiricism to therapeutic trials. Or how statistical methods can contribute to the improvement of therapeutic protocols in cervicofacial oncology].
    Cachin Y; Flamant R; Richard J; Sancho-Garnier H
    Ann Otolaryngol Chir Cervicofac; 1982; 99(1-2):47-52. PubMed ID: 7103330
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.